Impact of Adjuvant Therapy Type on Survival in Stage II/III Rectal Cancer Without Preoperative Chemoradiation: A Korean Multicenter Retrospective Study.

摘要: PURPOSE This study compared the oncologic impact of postoperative chemotherapy and chemoradiotherapy on patients with rectal cancer without preoperative chemoradiation. METHODS retrospective analyzed 713 a mean follow-up 58 months who had undergone radical resection for stage II/III treatment in nine hospitals from January 2004 to December 2009. The population was categorized group (CG, n = 460) (CRG, 253). Five-year overall survival (OS) disease-free (DFS) were analyzed, independent factors predicting identified. RESULTS CRG significantly younger (P < 0.001) greater incidences low III disease 0.001). OS 0.024) DFS 0.012) higher CG II disease; however, they not different disease. In multivariate analysis, predictive male sex, abdominoperineal resection, tumor-positive circumferential margin DFS. However, adjuvant therapy type did independently affect (hazard ratio [HR], 1.243; 95% confidence interval [CI], 0.794-1.945; P 0.341) (HR, 1.091; CI, 0.810-1.470; 0.566). CONCLUSION Adjuvant neoadjuvant chemoradiotherapy. These results suggest that can be chosen based patient's condition policies surgeons hospital facilities.